Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00001214
Other study ID # 860088
Secondary ID 86-H-0088
Status Completed
Phase
First received
Last updated
Start date April 30, 1986
Est. completion date August 17, 2020

Study information

Verified date August 2020
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Aplastic anemia is a condition in which the cells normally found in blood are greatly decreased. The normal levels of white blood cells, red blood cells, and platelets are much lower in patients with aplastic anemia.

Because of these low levels of blood cells, patients with aplastic anemia have a variety of immune system abnormalities. However, low levels of blood cells make it difficult to collect specialized white blood cells (mononuclear cells) for research studies.

This study was designed to collect lymphocytes from patients with low levels of all blood cells (pancytopenia) for use in research. Patients participating in the study will undergo a special procedure known as lymphapheresis. During lymphapheresis blood is taken from the patient in a manner similar to blood donation. The white blood cells are selectively removed by spinning (centrifugation), and the remaining red blood cells and platelets are placed back (re-infused) into the donor s blood stream.

Patients participating in this study will not benefit directly from it. However, cells collected in this study may increase scientific knowledge and improve understanding and treatment for diseases like aplastic anemia.


Description:

Patients with aplastic anemia, myelodysplasia, and other marrow failure syndromes have a variety of immunologic abnormalities including lymphocyte phenotypic and lymphokine production dysregulation. Because of their low blood counts, it has been difficult to obtain sufficient peripheral blood mononuclear cells for research studies. Patients agreeing to this protocol will be lymphapheresed the equivalent of one or two units of cells (approximately 1-2 x 10(8) cells), which will be used for research purposes.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date August 17, 2020
Est. primary completion date January 19, 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility - INCLUSION CRITERIA:

All patients with aplastic anemia or other bone marrow failure in which we would not expect to obtain 1 X 10(8) mononuclear cells from 100 mls of peripheral blood (i.e. an absolute lymphocyte count approximately less than 2000 per mm(3)).

Age greater than or equal to 18.

EXCLUSION CRITERIA:

Patients unable to comprehend the investigational nature of the procedure.

Patients unable to tolerate a temporary reduction of blood volume the equivalent of one unit of blood.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Goal was to obtain adequate numbers of cells for laboratory studies from pancytopenic patients in whom simple phlebotomy is inadequate. To obtain enough cells if phlebotomy inadequate. 1 day
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05473650 - Spectrum of Hematological Disorders in Pediatrics
Completed NCT00001398 - Stem Cell Factor Medication for Aplastic Anemia Phase 1
Completed NCT00260689 - Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia Phase 2
Completed NCT00000597 - Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Phase 3
Not yet recruiting NCT03521947 - Management of Childhood Pancytopenia
Completed NCT00001399 - Gene Therapy for the Treatment of Fanconi's Anemia Type C Phase 1
Completed NCT01187017 - A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Phase 1/Phase 2
Completed NCT01193283 - Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Phase 1/Phase 2